Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Location: United States, California, South San Francisco
Employees: 501-1000
Founded date: 2011
Investors 3
Mentions in press and media 20
| Date | Title | Description |
| 05.08.2022 | Pfizer in talks to buy sickle cell drug maker Global Blood Therapeutics for $5 billion, report | With billions of dollars from the covid vaccine windfall, pharmaceutical giant Pfizer is reportedly in late-stage negotiations to buy the drug maker Global Blood Therapeutics (GBT) for $5 billion, The Wall Street Journal reported Friday. T... |
| 20.12.2021 | Global Blood Therapeutics - U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease | SOUTH SAN FRANCISCO, Calif. - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of a supplemental New Drug Application (sNDA) for Oxbryta (voxelotor) t... |
| 17.12.2021 | Global Blood Therapeutics : U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease - Form ... | U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease New dispersible tablet dosage form also approved Oxbryta is the first medic... |
| 17.12.2021 | GBT's Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older | European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cau... |
| 17.12.2021 | U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease | New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NA... |
| 17.12.2021 | GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older | European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cau... |
| 13.12.2021 | Global Blood Therapeutics : Press Release, dated December 13, 2021 - Form 8-K | GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg ... |
| 13.12.2021 | GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition | GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies of SCD patients and healthy volunteers St... |
| 30.10.2021 | GBT Mourns the Loss of Sickle Cell Warrior Hertz Nazaire | PDF Version SOUTH SAN FRANCISCO, Calif. - October 29, 2021 - Global Blood Therapeutics, Inc. (GBT) was deeply saddened to learn that our dear friend and sickle cell warrior Hertz Nazaire passed away today. Our thoughts are with his family a... |
| 08.09.2021 | Global Blood Therapeutics : U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11 | SOUTH SAN FRANCISCO - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the company's supplemental New Drug Application (sNDA) seeking accelerat... |
Show more